Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc.

RNA·NASDAQ

$12.17

-1.3%
HealthcareBiotechnology

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

At a Glance

Live Snapshot
Market Cap$208.18M
EPS-4.4800
P/E Ratio-2.72
Earnings Date09/02/2026

rna

Selling, General and Administrative Expenses

Last Annual Value

41.68M

3-Year CAGR

3%

5-Year CAGR

25%

10-Year CAGR

33%

Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. Competitors Analysis of Selling, General and Administrative Expenses

RNA · NASDAQ
CompanySelling, General and Administrative Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
41.68M
-8.4%9.7%N/A 
392.47M
10.4%N/A27.1%
MRNA logo
Moderna, Inc.
NASDAQ:MRNA
1.02B
-13.1%12.4%33.3%
NUVL logo
Nuvalent, Inc.
NASDAQ:NUVL
107.34M
43.6%59.9%N/A
1.81B
10.4%4.5%13.7%
194.94M
18.4%23.3%40.9%
284.27M
17.9%24.0%26.2%
415.10M
5.6%7.4%11.4%
813.83M
96.0%85.2%56.4%
Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. Fair Value Envelope

RNA · NASDAQ

Our analysis suggests that RNA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $12.17, this represents a potential HIDDEN relative to our calculated worth for Atrium Therapeutics, Inc..

Intrinsic Value
Current Price: $12.17